

Alan Dal Pra

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3184620/alan-dal-pra-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

66 papers	1,801 citations	18 h-index	42 g-index
77 ext. papers	2,266 ext. citations	5.4 avg, IF	4.34 L-index

#	Paper	IF	Citations
66	Levels of Evidence for Radiation Therapy Recommendations in the National Comprehensive Cancer Network (NCCN) Clinical Guidelines. <i>Advances in Radiation Oncology</i> , 2022 , 7, 100832	3.3	
65	The Impact of Pelvic Nodal Radiotherapy on Hematologic Toxicity: A Systematic Review with Focus on Leukopenia, Lymphopenia and Future Perspectives in Prostate Cancer Treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 168, 103497	7	3
64	Repeatability of CBCT radiomic features and their correlation with CT radiomic features for prostate cancer. <i>Medical Physics</i> , 2021 , 48, 2386-2399	4.4	4
63	Heterogeneity in Genomic Risk Assessment from Tissue Based Prognostic Signatures Used in the Biopsy Setting and the Impact of Magnetic Resonance Imaging Targeted Biopsy. <i>Journal of Urology</i> , 2021 , 205, 1344-1351	2.5	4
62	Validation of the decipher genomic classifier (GC) in SAKK 09/10: A phase III randomized trial of dose-escalated salvage radiotherapy (SRT) after radical prostatectomy (RP).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 5010-5010	2.2	0
61	Assessment of Knowledge-Based Planning for Prostate Intensity Modulated Proton Therapy. <i>International Journal of Particle Therapy</i> , 2021 , 8, 62-72	1.5	1
60	A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. <i>European Urology</i> , 2021 , 79, 374-383	10.2	28
59	Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). <i>Cancer Genetics</i> , 2021 , 258-259, 61-68	2.3	0
58	Assessment of daily dose accumulation for robustly optimized intensity modulated proton therapy treatment of prostate cancer. <i>Physica Medica</i> , 2021 , 81, 77-85	2.7	2
57	Segmentation of prostate and prostate zones using deep learning : A multi-MRI vendor analysis. <i>Strahlentherapie Und Onkologie</i> , 2020 , 196, 932-942	4.3	18
56	Using hormone therapy with salvage radiotherapy according to presalvage PSA levels. <i>Nature Reviews Urology</i> , 2020 , 17, 489-490	5.5	
55	Is checkpoint inhibitor pneumonitis underreported in patients with advanced non-small cell lung cancer (NSCLC) on PD-1 inhibitor monotherapy?. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9579-9579	2.2	1
54	Impacts of post-radiotherapy lymphocyte count on progression-free and overall survival in patients with stage III lung cancer. <i>Thoracic Cancer</i> , 2020 , 11, 3139-3144	3.2	4
53	Margin verification for hypofractionated prostate radiotherapy using a novel dose accumulation workflow and iterative CBCT. <i>Physica Medica</i> , 2020 , 77, 154-159	2.7	6
52	Radiation-Induced Lymphopenia Beyond the COVID-19 Pandemic. <i>Frontiers in Oncology</i> , 2020 , 10, 617303	3.3	3
51	Re: Carlo A. Bravi, Nicoal Fossati, Giorgio Gandaglia, et al. Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. <i>Eur Urol</i> 2020;78:661-9. <i>European Urology</i> , 2020 , 78, e221-e222	10.2	
50	Toxicity reduction required for MRI-guided radiotherapy to be cost-effective in the treatment of localized prostate cancer. <i>British Journal of Radiology</i> , 2020 , 93, 20200028	3.4	7

49	The role of radiomics in prostate cancer radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2020 , 196, 900-912	12.3	9
48	Disease Control With Delayed Salvage Radiotherapy for Macroscopic Local Recurrence Following Radical Prostatectomy. <i>Frontiers in Oncology</i> , 2019 , 9, 12	5.3	9
47	Re: Gañan Devos, Gert De Meerleer, Steven Joniau. Have We Entered the Era of Imaging Before Salvage Treatment for Recurrent Prostate Cancer? Eur Urol 2019;76:265-7. <i>European Urology</i> , 2019 , 76, e148-e149	10.2	
46	Radiotherapy for pelvic nodal recurrences after radical prostatectomy: patient selection in clinical practice. <i>Radiation Oncology</i> , 2019 , 14, 177	4.2	8
45	Can texture analysis of pre-immunotherapy CT imaging predict clinical outcomes for patients with advanced NSCLC treated with Nivolumab?. <i>Journal of Clinical Oncology</i> , 2019 , 37, e20720-e20720	2.2	2
44	Salvage radiotherapy for macroscopic local recurrences after radical prostatectomy : A national survey on patterns of practice. <i>Strahlentherapie Und Onkologie</i> , 2018 , 194, 9-16	4.3	11
43	Re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. Eur Urol 2017;72:910-7. <i>European Urology</i> , 2018 , 73, e34-e35	10.2	1
42	An Automated Multiparametric MRI Quantitative Imaging Prostate Habitat Risk Scoring System for Defining External Beam Radiation Therapy Boost Volumes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 102, 821-829	4	9
41	Protocol for serum exosomal miRNAs analysis in prostate cancer patients treated with radiotherapy. <i>Journal of Translational Medicine</i> , 2018 , 16, 223	8.5	43
40	SAKK 08/15-promet: Multicenter, randomized phase II trial of salvage radiotherapy +/- metformin for patients with prostate cancer after prostatectomy.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS157-TPS157	2.2	0
39	Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy: Results of the randomized trial SAKK 09/10. <i>Radiotherapy and Oncology</i> , 2018 , 126, 257-262	5.3	13
38	Contemporary role of postoperative radiotherapy for prostate cancer. <i>Translational Andrology and Urology</i> , 2018 , 7, 399-413	2.3	5
37	Relation of baseline neutrophil-to-lymphocyte ratio to survival and toxicity in head and neck cancer patients treated with (chemo-) radiation. <i>Radiation Oncology</i> , 2018 , 13, 216	4.2	21
36	Magnetic resonance imaging (MRI)-based radiomics for prostate cancer radiotherapy. <i>Translational Andrology and Urology</i> , 2018 , 7, 445-458	2.3	23
35	Genomic hallmarks of localized, non-indolent prostate cancer. <i>Nature</i> , 2017 , 541, 359-364	50.4	320
34	A Prostate Cancer "Nimbofus": Genomic Instability and SCHLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. <i>European Urology</i> , 2017 , 72, 665-674	10.2	98
33	T1-2 glottic cancer treated with radiotherapy and/or surgery. <i>Strahlentherapie Und Onkologie</i> , 2017 , 193, 995-1004	4.3	16
32	Exosomes and Exosomal MicroRNAs in Prostate Cancer Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 98, 982-995	4	41

31	Primary tumor volume delineation in head and neck cancer: missing the tip of the iceberg?. <i>Radiation Oncology</i> , 2017 , 12, 102	4.2	2
30	Outcomes in Advanced Head and Neck Cancer Treated with Up-front Neck Dissection prior to (Chemo)Radiotherapy. <i>Otolaryngology - Head and Neck Surgery</i> , 2016 , 154, 300-8	5.5	9
29	Role of fluorine-18 fluorodeoxyglucose PET/CT in head and neck oncology: the point of view of the radiation oncologist. <i>British Journal of Radiology</i> , 2016 , 89, 20160217	3.4	33
28	Portfolio of prospective clinical trials including brachytherapy: an analysis of the ClinicalTrials.gov database. <i>Radiation Oncology</i> , 2016 , 11, 48	4.2	9
27	Liver Failure After Abdominal Irradiation: Identifying the Right Suspects. <i>Journal of Clinical Oncology</i> , 2016 , 34, e80-3	2.2	1
26	Up-front neck dissection followed by definitive (chemo)-radiotherapy in head and neck squamous cell carcinoma: Rationale, complications, toxicity rates, and oncological outcomes - A systematic review. <i>Radiotherapy and Oncology</i> , 2016 , 119, 185-93	5.3	18
25	Copy number alterations of P53, RB1, and MDM2 as prognostic markers in intermediate-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 117-117	2.2	
24	Copy number alterations of DNA mismatch repair (MMR) genes as novel prognostic markers in localised prostate cancer (CaP).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 96-96	2.2	
23	Prognostic value of copy-number alterations of the Cohesin complex in intermediate-risk prostate cancer recurrence.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 49-49	2.2	
22	Combinatorial genomic and pathological indices for integrated stratification of unfavorable intermediate-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5051-5051	2.2	
21	Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer. <i>Frontiers in Oncology</i> , 2016 , 6, 24	5.3	17
20	Urethral strictures after radiation therapy for prostate cancer. <i>Investigative and Clinical Urology</i> , 2016 , 57, 309-15	1.9	13
19	Re: William C. Jackson, Matthew J. Schipper, Skyler B. Johnson, et al. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. <i>Eur Urol</i> 2016;69:50-7. Re: Ronald C. Chen. Postprostatectomy Radiotherapy: Whether and How Long to Give Concurrent Androgen Deprivation Therapy. <i>Eur Urol</i> 2016;69:74-75	10.2	
18	Prognostic value of biochemical response to neoadjuvant androgen deprivation before external beam radiotherapy for prostate cancer: A systematic review of the literature. <i>Cancer Treatment Reviews</i> , 2016 , 46, 35-41	14.4	15
17	Prostate cancer radiation therapy: A physician's perspective. <i>Physica Medica</i> , 2016 , 32, 438-45	2.7	19
16	Definitive intensity modulated radiotherapy in locally advanced hypopharyngeal and laryngeal squamous cell carcinoma: mature treatment results and patterns of locoregional failure. <i>Radiation Oncology</i> , 2015 , 10, 20	4.2	5
15	Synergistic action of image-guided radiotherapy and androgen deprivation therapy. <i>Nature Reviews Urology</i> , 2015 , 12, 193-204	5.5	30
14	Clinical Perspectives from Randomized Phase 3 Trials on Prostate Cancer: An Analysis of the ClinicalTrials.gov Database. <i>European Urology Focus</i> , 2015 , 1, 173-184	5.1	10

13	Spatial genomic heterogeneity within localized, multifocal prostate cancer. <i>Nature Genetics</i> , 2015 , 47, 736-45	36.3	306
12	Consensus and differences in primary radiotherapy for localized and locally advanced prostate cancer in Switzerland: A survey on patterns of practice. <i>Strahlentherapie Und Onkologie</i> , 2015 , 191, 778-86	4.3	16
11	Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. <i>Lancet Oncology</i> , 2014 , 15, 1521-1532	21.7	218
10	Objective consensus from decision trees. <i>Radiation Oncology</i> , 2014 , 9, 270	4.2	34
9	Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. In regard to Freedland et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 88, 237-40	4	4
8	Intratumoral hypoxia as the genesis of genetic instability and clinical prognosis in prostate cancer. <i>Advances in Experimental Medicine and Biology</i> , 2014 , 772, 189-204	3.6	26
7	Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. <i>Clinical Cancer Research</i> , 2013 , 19, 6741-50	12.9	213
6	Does transperitoneal minimally invasive radical prostatectomy increase the amount of small bowel receiving salvage radiation?. <i>Canadian Urological Association Journal</i> , 2013 , 7, 444-8	1.2	2
5	TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair. <i>Clinical Cancer Research</i> , 2013 , 19, 5202-9	12.9	34
4	Hypoxia, androgen deprivation and systemic metastases in prostate cancer (in response to "Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxivity dynamic MRI": in regard to Alonzi R et al. (Int J Radiat Oncol Biol Phys 2011;80(3): 721-727). <i>International Journal of Radiation Oncology Biology Physics</i> , 2011 , 80, 721-727	4	3
3	Treating intermediate-risk prostate cancer with hypofractionated external beam radiotherapy alone. <i>Radiotherapy and Oncology</i> , 2011 , 101, 486-9	5.3	14
2	Stereotactic fractionated radiotherapy in the treatment of juxtapapillary choroidal melanoma: the McGill University experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011 , 81, e455-62	4.2	19
1	Radiation therapy and androgen deprivation in the management of high risk prostate cancer. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2011 , 37, 161-75; discussion 176-9	2	11